Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04442126 · OUTCOME

Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v5.0

A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors · Source last updated 2025-05-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
From baseline to up to 12 weeks post last dose, up to 48 weeks.

What was measured

Frequency and severity of adverse events

Analysis population: Participant with any TREA

Groups in this outcome

Part A Dose Level 1 NM21-1490-Q2W 0.15mg

Part A Dose Level 1 NM21-1490-Q2W 0.15mg

Part A Dose Level 2 NM21-1490-Q2W 1.5mg

Part A Dose Level 2 NM21-1490-Q2W 1.5mg

Part A Dose Level 3 NM21-1490-Q2W 8mg

Part A Dose Level 3 NM21-1490-Q2W 8mg

Part A Dose Level 4 NM21-1490-Q2W 24mg

Part A Dose Level 4 NM21-1490-Q2W 24mg

Part A Dose Level 5 NM21-1490-Q2W 80mg

Part A Dose Level 5 NM21-1490-Q2W 80mg

Part A Dose Level 6 NM21-1490-Q2W 240mg

Part A Dose Level 6 NM21-1490-Q2W 240mg

Part A Dose Level 7 NM21-1490-Q2W 800mg

Part A Dose Level 7 NM21-1490-Q2W 800mg

Part A2 NM32-1480-Q2W

Part A2 NM32-1480-Q2W 1400mg

Part B NM32-1480-Q2W

Part B NM32-1480-Q2W 800mg

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part A Dose Level 1 NM21-1490-Q2W 0.15mg1
Part A Dose Level 2 NM21-1490-Q2W 1.5mg1
Part A Dose Level 3 NM21-1490-Q2W 8mg3
Part A Dose Level 4 NM21-1490-Q2W 24mg3
Part A Dose Level 5 NM21-1490-Q2W 80mg6
Part A Dose Level 6 NM21-1490-Q2W 240mg3
Part A Dose Level 7 NM21-1490-Q2W 800mg9
Part A2 NM32-1480-Q2W5
Part B NM32-1480-Q2W21

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part A Dose Level 1 NM21-1490-Q2W 0.15mg1Not reportedNot reportedNot reportedNot reported
Part A Dose Level 2 NM21-1490-Q2W 1.5mg1Not reportedNot reportedNot reportedNot reported
Part A Dose Level 3 NM21-1490-Q2W 8mg3Not reportedNot reportedNot reportedNot reported
Part A Dose Level 4 NM21-1490-Q2W 24mg3Not reportedNot reportedNot reportedNot reported
Part A Dose Level 5 NM21-1490-Q2W 80mg5Not reportedNot reportedNot reportedNot reported
Part A Dose Level 6 NM21-1490-Q2W 240mg3Not reportedNot reportedNot reportedNot reported
Part A Dose Level 7 NM21-1490-Q2W 800mg9Not reportedNot reportedNot reportedNot reported
Part A2 NM32-1480-Q2W5Not reportedNot reportedNot reportedNot reported
Part B NM32-1480-Q2W16Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        1
      3. group Id
        OG002
        value
        3
      4. group Id
        OG003
        value
        3
      5. group Id
        OG004
        value
        5
      6. group Id
        OG005
        value
        3
      7. group Id
        OG006
        value
        9
      8. group Id
        OG007
        value
        5
      9. group Id
        OG008
        value
        16
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    2. group Id
      OG001
      value
      1
    3. group Id
      OG002
      value
      3
    4. group Id
      OG003
      value
      3
    5. group Id
      OG004
      value
      6
    6. group Id
      OG005
      value
      3
    7. group Id
      OG006
      value
      9
    8. group Id
      OG007
      value
      5
    9. group Id
      OG008
      value
      21
    units
    Participants
description
Frequency and severity of adverse events
groups
  1. description
    Part A Dose Level 1 NM21-1490-Q2W 0.15mg
    id
    OG000
    title
    Part A Dose Level 1 NM21-1490-Q2W 0.15mg
  2. description
    Part A Dose Level 2 NM21-1490-Q2W 1.5mg
    id
    OG001
    title
    Part A Dose Level 2 NM21-1490-Q2W 1.5mg
  3. description
    Part A Dose Level 3 NM21-1490-Q2W 8mg
    id
    OG002
    title
    Part A Dose Level 3 NM21-1490-Q2W 8mg
  4. description
    Part A Dose Level 4 NM21-1490-Q2W 24mg
    id
    OG003
    title
    Part A Dose Level 4 NM21-1490-Q2W 24mg
  5. description
    Part A Dose Level 5 NM21-1490-Q2W 80mg
    id
    OG004
    title
    Part A Dose Level 5 NM21-1490-Q2W 80mg
  6. description
    Part A Dose Level 6 NM21-1490-Q2W 240mg
    id
    OG005
    title
    Part A Dose Level 6 NM21-1490-Q2W 240mg
  7. description
    Part A Dose Level 7 NM21-1490-Q2W 800mg
    id
    OG006
    title
    Part A Dose Level 7 NM21-1490-Q2W 800mg
  8. description
    Part A2 NM32-1480-Q2W 1400mg
    id
    OG007
    title
    Part A2 NM32-1480-Q2W
  9. description
    Part B NM32-1480-Q2W 800mg
    id
    OG008
    title
    Part B NM32-1480-Q2W
param Type
NUMBER
population Description
Participant with any TREA
reporting Status
POSTED
time Frame
From baseline to up to 12 weeks post last dose, up to 48 weeks.
title
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v5.0
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice